Erenumab in highly therapy-refractory migraine patients: First German real-world evidence | The Journal of Headache and Pain | Full Text

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence | The Journal of Headache and Pain | Full Text

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding ef...

Authors:Armin Scheffler, Olga Messel, Sebastian Wurthmann, Michael Nsaka, Christoph Kleinschnitz, Martin Glas, Steffen Naegel and Dagny Holle

Citation:The Journal of Headache and Pain 2020 21:84

Content type:Research article

 

Published on: 3 July 2020

• ViewFull Text
 
• ViewPDF